Teva Can't Escape Insurers' Copaxone Generic Delay Case
By Matthew Perlman · January 23, 2024, 8:11 PM EST
A Vermont federal court has refused to toss a proposed class action from insurers accusing Teva Pharmaceuticals of delaying generic versions of multiple sclerosis treatment Copaxone but trimmed several claims under...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login